Sanofi 'surprised' by PAI Partners' raised bid for Opella unit
PAI Partners seeks to outbid CD&R for Opella stake
Sanofi's revised bid valid until Sunday night, source says
Company says new offer came outside regular process
Unions fear job losses, call for strike at Sanofi's plants
Updates with reaction from Sanofi to the new offer in paragraphs 1-6
PARIS, Oct 17 (Reuters) - French drugmaker SanofiSASY.PA said on Thursday it was "surprised" by a renewed, higher offer for its consumer arm Opella from private equity firm PAI Partners, saying the move came after the bidding deadline for the business had passed.
PAI is seeking to outbid U.S. rival Clayton Dubilier & Rice (CD&R) for a controlling 50% stake in Opella, the maker of one of France's most-sold painkillers, Doliprane, a source earlier told Reuters, confirming media reports.
Sanofi remained reserved, saying in a statement sent to journalists on Thursday that it was "surprised that an 'improved offer' is being made now, outside the timeframe and the governance process that framed the decision."
All candidates had the same opportunity to submit their best offers within the process deadline, the company said.
BID HIKED BY 2OO MILLION EUROS
The source told Reuters that thePAI-led consortium had hiked its bid by 200 million euros ($217.2 million) in a revised offer sent earlier on Thursday to Sanofi Chairman Frederic Oudea.
It said the new bid is valid until Sunday night, but declinedto elaborate on the exact price offered for the stake in Opella, which is valued at more than 15 billion euros.
CD&R declined to comment.
Sanofi, France's biggest pharmaceutical group, said last week that itwas in talks with CD&R for the sale of a 50% controlling stake inOpella, triggering criticism from both the right and left of France's political spectrum over concerns France could lose a strategic asset.
The French government made pledges during the COVID-19 pandemic to restore self-sufficiency in healthcare. Labour unions had called for a strike at Sanofi's plants in France on Thursday amid fears a sale to CD&R could result in job losses.
"Doliprane must stay in France. It belongs to the French," CFDT union coordinator and Sanofi production technician Adil Bensetra said outside the Compiegne plant in northern France during Thursday's protest.
"We have already given up too much in terms of French industry. ... We cannot give up health," he said.
"We have elections in the United States with a Donald Trump who has always had an 'American First' policy," he added. "(Trump) could say that all the manufacturing today of these products that are made in France and Europe should be relocated to the United States."
In its revised bid, PAI pledged to preserve headcount and raise investments at Opella's French production sites of Lisieux in Normandy and Compiegne, the source said. It also vowed to keep Opella's headquarters in France, the same source added.
($1 = 0.9204 euros)
Reporting by Mathieu Rosemain, Dominique Patton and Lucien Libert; Editing by Mark Potter, Jan Harvey and Mark Porter
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
